Myriad Genetics (MYGN) Stock Analysis & Winston Score

Myriad Genetics is a healthcare company that runs genetic tests for patients and doctors. Its most well-known products are tests that check for gene mutations linked to hereditary cancers, like the BRACAnalysis test for BRCA1 and BRCA2 mutations, which can signal higher risk for breast and ovarian cancer. The company also offers tests for mental health medication matching and prenatal conditions, selling primarily to hospitals, clinics, and physicians across the United States. Myriad makes money by charging for each genetic test it performs, with payment coming from insurance companies, government programs like Medicare and Medicaid, and patients directly. It operates mainly in the US, with a small international presence, and generates roughly $700–800 million in annual revenue. The company has built a large proprietary database of genetic variants, which gives it some scientific edge, but it faces intense competition from rivals like Labcorp and Invitae, and its ongoing operating losses mean improving reimbursement rates and controlling costs are critical challenges ahead.